Kai Zhao, Madita Braun, Leonie Meyer, Katharina Otte, Hartmann Raifer, Frederik Helmprobst, Vincent Möschl, Axel Pagenstecher, Hans Urban, Michael W Ronellenfitsch, Joachim P Steinbach, Jelena Pesek, Bernhard Watzer, Wolfgang A Nockher, R Verena Taudte, Andreas Neubauer, Christopher Nimsky, Jörg W Bartsch, Tillmann Rusch
Adjuvant treatment for Glioblastoma Grade 4 with Temozolomide (TMZ) inevitably fails due to therapeutic resistance, necessitating new approaches. Apoptosis induction in GB cells is inefficient, due to an excess of anti-apoptotic XPO1/Bcl-2-family proteins. We assessed TMZ, Methotrexate (MTX), and Cytarabine (Ara-C) (apoptosis inducers) combined with XPO1/Bcl-2/Mcl-1-inhibitors (apoptosis rescue) in GB cell lines and primary GB stem-like cells (GSCs). Using CellTiter-Glo® and Caspase-3 activity assays, we generated dose-response curves and analyzed the gene and protein regulation of anti-apoptotic proteins via PCR and Western blots...
April 4, 2024: Cells